[Skip to content]

Share this page

  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
PA Consulting Group MCA Awards - 2012 Award Winner
Contact PA Consulting Group now for more information

United Kingdom
+44 (0)20 7333 5869

United States
+1 212 973 5943

or for further information visit www.paconsulting.com/contact
Search our Site or contact us
contact us now
.
Picture of people in a laboratory

"PA contributed to the success of the project: by understanding our product and process development needs, through application of their technical expertise, and by excellent teamwork."
PROJECT OFFICE MANAGER, METRIS

Metris – developing a novel vaginal drug delivery system

PA Consulting Group was asked by Metris Therapeutics, a specialist pharmaceutical company focusing on women’s healthcare, to assist it with establishing a manufacturing process for products to be used in the treatment of benign gynaecological conditions such as menorrhagia/dysmenorrhea, using a novel vaginal drug delivery system. A patent covering the concept of the vaginal delivery system (VDS) was previously filed.

PA’s initial brief was to turn the concept into a prototype for use in preclinical testing to determine whether the physical characteristics of the product in vitro lent themselves to a safe and effective delivery system.

PA  also advised on clinical and regulatory aspects of the clinical development programme.

From significant experience of running product development programmes involving multiple suppliers, PA recognised the need to establish a formal project team structure comprising function specific workstreams, whose activities would be monitored by a project office and governed by a project steering committee.

This structure and PA’s rapid prototyping ability were major contributory factors to ensuring that the project team met the objectives of taking the concept to phase-one clinical trials within 16 months (including the successful submission of an IND application), and to phase-two trials within 24 months.

To find out more about our drug delivery capability, please contact us now.